Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04042714 · ClinicalTrials.gov registry record · Phase 2
TAS-102 in Extrapulmonary Neuroendocrine Carcinoma
A Phase 2 study, sponsored by Baylor Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT04042714 is a Phase 2 study that was terminated before completion, run by Baylor Research Institute. The registered enrollment target is 14 participants.
The verdict
NCT04042714, a Phase 2 study, was terminated before completion, sponsored by Baylor Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and efficacy of drug, TAS-102 (trifluridine/tipiracil), in patients with extrapulmonary (outside the lung) high-grade neuroendocrine cancer. TAS-102 demonstrated improved survival and tolerability in patients with colorectal cancer and is currently approved by the FDA and marketed under the brand name Lonsurf for the treatment of patients with metastatic colorectal cancer (mCRC). Recently, a study evaluating TAS-102 showed a case of complete remission of high-grade NEC. Given the safety profile of TAS-102 and the remarkable single agent activity in a disease with otherwise dismal outcomes, we hope that TAS-102 may show tolerability and efficacy in neuro-endocrine cancer and propose further exploration in patients with extrapulmonary (outside the lung) high-grade neuroendocrine cancer.
Interventions
- DRUG All patients- TAS-102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2019-08-15 |
| Est. Completion | 2025-10-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04042714
The ClinicalTrials.gov registry entry for NCT04042714 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor Research Institute, which has 180 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which All patients- TAS-102 is the first listed.
NCT04042714 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04042714 about?
NCT04042714 is a clinical study titled "TAS-102 in Extrapulmonary Neuroendocrine Carcinoma". The purpose of this study is to test the safety and efficacy of drug, TAS-102 (trifluridine/tipiracil), in patients with extrapulmonary (outside the lung) high-grade neuroendocrine cancer. TAS-102 demonstrated improved survival and tolerability in patients with colorectal cancer and is currently app...
What is the current status of trial NCT04042714?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2019-08-15. Estimated completion is 2025-10-15.
What interventions are being tested in trial NCT04042714?
The interventions under investigation include: All patients- TAS-102 (DRUG).
Who is sponsoring clinical trial NCT04042714?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.